Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial
暂无分享,去创建一个
K. Anstrom | C. Cannon | T. Henry | E. Peterson | G. Fonarow | N. Choudhry | D. Cohen | Tracy Y. Wang | Durgesh D. Bhandary | Naeem D. Khan | L. Kaltenbach | D. Cohen | D. Cohen
[1] Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial. , 2020, JAMA cardiology.
[2] E. Peterson,et al. Translating the Secondary Prevention Therapeutic Boom Into Action. , 2020, JAMA cardiology.
[3] K. Anstrom,et al. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial. , 2019, JAMA cardiology.
[4] Andrew S. Boozary,et al. Effect on Treatment Adherence of Distributing Essential Medicines at No Charge , 2019, JAMA internal medicine.
[5] Neha J. Pagidipati,et al. Opportunities for improving use of evidence‐based therapy in patients with type 2 diabetes and cardiovascular disease , 2019, Clinical cardiology.
[6] H. Jneid,et al. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry , 2018, Journal of the American Heart Association.
[7] E. Peterson,et al. Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality , 2018, Circulation.
[8] K. Ferdinand,et al. Disparities in hypertension and cardiovascular disease in blacks: The critical role of medication adherence , 2017, Journal of clinical hypertension.
[9] J. Cigarroa,et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, The Journal of thoracic and cardiovascular surgery.
[10] K. Anstrom,et al. Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and , 2016, Circulation. Cardiovascular interventions.
[11] E. Peterson,et al. Treatment, Outcomes, and Adherence to Medication Regimens Among Dual Medicare-Medicaid-Eligible Adults With Myocardial Infarction. , 2016, JAMA cardiology.
[12] K. Anstrom,et al. Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. , 2016, American heart journal.
[13] Susan E. Spratt,et al. The agreement of patient-reported versus observed medication adherence in type 2 diabetes mellitus (T2DM) , 2016, BMJ Open Diabetes Research and Care.
[14] E. Peterson,et al. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. , 2016, JAMA cardiology.
[15] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[16] T. Henry,et al. Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities from the TRANSLATE-ACS Study , 2015 .
[17] T. Henry,et al. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. , 2015, American heart journal.
[18] P. Whelton,et al. Differences in cardiovascular disease risk when antihypertensive medication adherence is assessed by pharmacy fill versus self-report: the Cohort Study of Medication Adherence among Older Adults (CoSMO) , 2015, Journal of hypertension.
[19] L. Mauri,et al. Adherence to Dual Antiplatelet Therapy After Coronary Stenting: A Systematic Review , 2014, Clinical cardiology.
[20] Antonio Colombo,et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.
[21] Paul Heidenreich,et al. Cardiovascular care facts: a report from the national cardiovascular data registry: 2011. , 2013, Journal of the American College of Cardiology.
[22] C. V. Woerkum,et al. Cost Effectiveness of Medication Adherence-Enhancing Interventions: A Systematic Review of Trial-Based Economic Evaluations , 2013, PharmacoEconomics.
[23] Morgen M. Miller,et al. Computing Adjusted Risk Ratios and Risk Differences in Stata , 2013 .
[24] G. Piaggio,et al. Consort 2010 statement: extension to cluster randomised trials , 2012, BMJ : British Medical Journal.
[25] Lonny Reisman,et al. Full coverage for preventive medications after myocardial infarction. , 2011, The New England journal of medicine.
[26] Inger Ekman,et al. Medication adherence: a call for action. , 2011, American heart journal.
[27] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[28] P. Austin. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.
[29] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[30] Peter C Austin,et al. Some Methods of Propensity‐Score Matching had Superior Performance to Others: Results of an Empirical Investigation and Monte Carlo simulations , 2009, Biometrical journal. Biometrische Zeitschrift.
[31] E. Norton,et al. What's the Risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. , 2009, Health services research.
[32] William H Shrank,et al. Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post–Myocardial Infarction Medicare Beneficiaries , 2008, Circulation.
[33] Ping Li,et al. Prevalence, Predictors, and Outcomes of Primary Nonadherence After Acute Myocardial Infarction , 2008, Circulation.
[34] A. Fendrick,et al. Impact of decreasing copayments on medication adherence within a disease management environment. , 2008, Health affairs.
[35] Anuja Roy,et al. Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[36] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[37] S. Spinler,et al. Antiplatelet Therapy in Patients with Unstable Angina and Non–ST‐Segment‐Elevation Myocardial Infarction: Findings from the CRUSADE National Quality Improvement Initiative , 2007, Pharmacotherapy.
[38] Harlan M. Krumholz,et al. Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry , 2006, Circulation.
[39] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.